Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2018-06-28 Director's Dealing
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
FORM4
Director's Dealing
2018-06-28 English
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as stock option plans. It includes details about the securities to be registered, the plan under which they are offered, and legal undertakings. It references incorporation by reference of other filings like 10-K and 10-Q but does not itself contain financial statements or earnings data. It is not an earnings release, annual report, or any other financial report but a registration statement related to capital raising through employee stock plans. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed registration information, confirming it is not a mere announcement or certification.
2018-06-25 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 18, 2018. It announces the entry into a material definitive agreement, specifically a Joint Venture and License Option Agreement between TG Therapeutics, Inc. and Novimmune SA. The content focuses on the details of this agreement, including payments, responsibilities, and licensing options. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document is an announcement of a significant corporate transaction related to collaboration and licensing, which fits the category of Capital/Financing Update (CAP) as it involves upfront payments, milestone payments, and licensing rights. The document length is under 5,000 characters and it is not merely announcing the publication of a report but providing substantive information about the agreement. Therefore, the appropriate classification is CAP with high confidence.
2018-06-20 English
SC 13D AMENDMENT NO. 2
Major Shareholding Notification
2018-06-18 English
FORM-4
Director's Dealing
2018-06-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes announcements of press releases about clinical data presentations and updated trial results, but does not contain financial statements or detailed financial analysis. The document is short (3203 characters) and primarily serves to announce events and attach press releases as exhibits. There is no indication of quarterly or annual financial results, management discussion, or audit information. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-06-18 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.